DGIdb - DOXORUBICIN Drug Record

DOXORUBICIN chembl:CHEMBL53463 ApprovedAntineoplasticImmunotherapy

Alternate Names:

RUBEX
VALRUBICIN IMPURITY, DOXORUBICIN
NSC-123127
ADRIAMYCIN
DOXIL
HYDROXYDAUNORUBICIN
ADRIBLASTINA
DOXORUBICIN
(1S,3S)-3-GLYCOLOYL-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1,2,3,4,6,11-HEXAHYDROTETRACEN-1-YL 3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSIDE
DOXORUBICIN HYDROCHLORIDE
(8S-CIS)-10-((3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-5,12-NAPHTHACENEDIONE
ADRIAMYCIN®
14-HYDROXYDAUNORUBICINE
DOXIL®
DOXORUBICINE
14-HYDROXYDAUNOMYCIN
DOXORUBICINUM
drugbank:00997
pubchem.compound:31703
chemidplus:23214-92-8
rxcui:3639
chembl:CHEMBL53463

Drug Info:

Year of Approval	1974
Drug Class	antineoplastic agents
FDA Approval	approved
Drug Class	Small Molecule
Drug Indications	antineoplastic agent

(6 More Sources)

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Vikhanskaya et al., 1995, Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes., Int. J. Cancer
Bosanquet et al., 2002, Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia., Leukemia
Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer
Kobrinsky et al., 2005, Successful treatment of doxorubicin and cisplatin resistant hepatoblastoma in a child with Beckwith-Wiedemann syndrome with high dose acetaminophen and N-acetylcysteine rescue., Pediatr Blood Cancer
Evdokimov NM et al., 2011, Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents., J Med Chem
Tan S et al., 2015, Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo) I/II inhibition., Bioorg Med Chem
Chhikara BS et al., 2012, Synthesis, anticancer activities, and cellular uptake studies of lipophilic derivatives of doxorubicin succinate., J Med Chem
Chen Z et al., 2010, A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis., J Med Chem
Hayashi et al., 2006, Enhancement of radiosensitivity by topoisomerase II inhibitor, amrubicin and amrubicinol, in human lung adenocarcinoma A549 cells and kinetics of apoptosis and necrosis induction., Int. J. Mol. Med.
Koehn et al., 2007, Differential regulation of DNA repair protein Rad51 in human tumour cell lines exposed to doxorubicin., Anticancer Drugs
Rody et al., 2007, Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response., Breast
Azarova et al., 2007, Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies., Proc. Natl. Acad. Sci. U.S.A.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Menendez et al., 2006, DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes., Int. J. Mol. Med.
Picaud et al., 2015, Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy., Cancer Res.
Wojnowski L et al., 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation
Jabbour-Leung et al., 2016, Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer., Mol. Cancer Ther.
Ohnstad et al., 2013, Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma., Cancer
Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.
Richter et al., 2015, WIP1 phosphatase as a potential therapeutic target in neuroblastoma., PLoS ONE
Yang et al., 2011, p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer., Int. J. Oncol.
Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther
Berns et al., 1998, Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer., Br. J. Cancer
Jackson et al., 2012, p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer., Cancer Cell
Davidovich P et al., 2015, Discovery of Novel Isatin-Based p53 Inducers., ACS Med Chem Lett
Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci
Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma
Cowin et al., 2012, LRP1B deletion in high-grade serous ovarian cancers is associated with acquired chemotherapy resistance to liposomal doxorubicin., Cancer Res.
Kalra S et al., 2018, Association of CYP2C192 and ALDH1A11/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
Bray J et al., 2010, Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide., Br J Cancer
Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Thorn CF et al., 2011, Doxorubicin pathways: pharmacodynamics and adverse effects., Pharmacogenet Genomics
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Bains OS et al., 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos
Gonzalez-Covarrubias V et al., 2009, Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors., Drug Metab Dispos
Lal S et al., 2008, CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
Ai et al., 2008, The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer., Carcinogenesis
Middlemas et al., 1999, Brain derived neurotrophic factor protects human neuroblastoma cells from DNA damaging agents., J. Neurooncol.
Navrkalova V et al., 2013, ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin., Haematologica
Yamaguchi et al., 2005, Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death., Oncol. Rep.
Sagone AL Jr et al., 1979, The effect of BCNU and adriamycin on normal and G6PD deficient erythrocytes., Am J Hematol
Allen JD et al., 2002, A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance., Cancer Res
Caronia D et al., 2011, Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic study., PLoS One
Ujházy et al., 1994, Ecto-5'-nucleotidase (CD73) in multidrug-resistant cell lines generated by doxorubicin., Int. J. Cancer
Kurabayashi et al., 1994, Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor MyoD. Involvement of Id gene induction., J. Biol. Chem.
Lee et al., 2006, Interplay between PI3K/Akt and MAPK signaling pathways in DNA-damaging drug-induced apoptosis., Biochim. Biophys. Acta
Basho et al., 2017, Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab., JAMA Oncol
Knuefermann et al., 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells., Oncogene
Mavrakis et al., 2008, Tumorigenic activity and therapeutic inhibition of Rheb GTPase., Genes Dev.
Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
Filipits et al., 2003, Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma., Clin. Cancer Res.
Serie DJ et al., 2017, Genome-wide association study of cardiotoxicity in the NCCTG N9831 (Alliance) adjuvant trastuzumab trial., Pharmacogenet Genomics
Megías-Vericat JE et al., 2018, Impact of NADPH oxidase functional polymorphisms in acute myeloid leukemia induction chemotherapy., Pharmacogenomics J
Hertz DL et al., 2016, Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines., Pharmacogenomics
Rossi D et al., 2009, Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21., Leukemia
Saadane et al., 1999, TAFII250, Egr-1, and D-type cyclin expression in mice and neonatal rat cardiomyocytes treated with doxorubicin., Am. J. Physiol.
Aversano et al., 1983, Histochemical alterations of acute and chronic doxorubicin cardiotoxicity., J. Mol. Cell. Cardiol.
Lebrecht et al., 2005, Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin., J. Pathol.
De Mattia E et al., 2016, Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine., Pharmacogenomics
Voon PJ et al., 2013, Correlation of aldo-ketoreductase (AKR) 1C3 genetic variant with doxorubicin pharmacodynamics in Asian breast cancer patients., Br J Clin Pharmacol
Bains OS et al., 2010, Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin., J Pharmacol Exp Ther
Koschmann et al., 2016, ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma., Sci Transl Med
Williams et al., 2007, Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions., BMC Mol. Biol.
Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem
Shchekotikhin AE et al., 2007, Naphthoindole-based analogues of tryptophan and tryptamine: synthesis and cytotoxic properties., Bioorg Med Chem
Bolognese A et al., 2008, Antitumor agents 6. Synthesis, structure-activity relationships, and biological evaluation of spiro[imidazolidine-4,3'-thieno[2,3-g]quinoline]-tetraones and spiro[thieno[2,3-g]quinoline-3,5'-[1,2,4]triazinane]-tetraones with potent antiproliferative activity., J Med Chem
Paciucci et al., 1991, Immunotherapy with IL2 by constant infusion and weekly doxorubicin., Am. J. Clin. Oncol.
Peck et al., 2001, Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin., J. Clin. Oncol.
Jordheim LP et al., 2015, Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma., Haematologica
Lal S et al., 2008, Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients., Cancer Sci
Gregers J et al., 2015, Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia., Pharmacogenomics J
Maggini V et al., 2008, MDR1 diplotypes as prognostic markers in multiple myeloma., Pharmacogenet Genomics
Sánchez-Tilló et al., 2014, The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma., Cell Death Differ.
Wang et al., 2008, Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2., Carcinogenesis
Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
Ohno et al., 2001, Expression of functional lung resistance--related protein predicts poor outcome in adult T-cell leukemia., Blood
Sayed-Ahmed et al., 2001, Increased plasma endothelin-1 and cardiac nitric oxide during doxorubicin-induced cardiomyopathy., Pharmacol. Toxicol.
Niiya et al., 2004, Involvement of ERK1/2 and p38 MAP kinase in doxorubicin-induced uPA expression in human RC-K8 lymphoma and NCI-H69 small cell lung carcinoma cells., Oncology
Mourali et al., 2006, Anaplastic lymphoma kinase is a dependence receptor whose proapoptotic functions are activated by caspase cleavage., Mol. Cell. Biol.
Lu et al., 2017, The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model., Cancer Lett.
Hawinkels et al., 2016, Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors., Clin. Cancer Res.
Malugin et al., HPMA copolymer-bound doxorubicin induces apoptosis in ovarian carcinoma cells by the disruption of mitochondrial function., Mol. Pharm.
Lu et al., 2005, Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism., Mol. Pharmacol.
Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
Ciftci et al., 2003, Growth factors and chemotherapeutic modulation of breast cancer cells., J. Pharm. Pharmacol.
Vinik et al., 2016, Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial., Target Oncol
Wong TW et al., 2000, The decrease of mitochondrial NADH dehydrogenease and drug induced apoptosis in doxorubicin resistant A431 cells., Life Sci
Vásquez-Vivar J et al., 1997, Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin., Biochemistry
Yang et al., Effects of doxorubicin on pp60c-src kinase activity in polyoma virus MT antigen transformed cells., Anticancer Res.
Jamieson D et al., 2011, Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy., Pharmacogenet Genomics
Kurz et al., 2004, Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species., J. Biol. Chem.
Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
Reichwagen A et al., 2015, Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma., Pharmacogenomics
Kozakai Y et al., 2014, Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line., Bioorg Med Chem Lett
Faraji A et al., 2016, Association of ABCB1 and SLC22A16 Gene Polymorphisms with Incidence of Doxorubicin-Induced Febrile Neutropenia: A Survey of Iranian Breast Cancer Patients., PLoS One
Lal S et al., 2007, Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients., Pharmacogenomics
Gelderblom H et al., 2014, Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study., Eur J Cancer
Johnson et al., 2015, HDAC1,2 inhibition impairs EZH2- and BBAP-mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma., Oncotarget
Bains OS et al., 2010, Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism., J Pharmacol Exp Ther
Fan L et al., 2008, Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity., Pharmacogenet Genomics
Harbottle A et al., 2001, Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance., Int J Cancer
Low SK et al., 2009, Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients., J Hum Genet
Jaboin et al., 2002, Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway., Cancer Res.
Isaacs et al., 1997, Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin., J. Clin. Oncol.
Schröterová et al., 2004, The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro., Physiol Res

DOXORUBICIN NCF4

Interaction Score: 2.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28763429 28485375 26799497 21048526 19448608 16330681

Sources:
PharmGKB
DOXORUBICIN CYBA

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28485375 25823784 21048526 19448608 16330681

Sources:
PharmGKB
DOXORUBICIN PPM1D

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25466181

Sources:
DTC
DOXORUBICIN AKR1A1

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526

Sources:
PharmGKB
DOXORUBICIN SP3

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17511886

Sources:
NCI
DOXORUBICIN TAF1

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10070062

Sources:
NCI
DOXORUBICIN LRP1B

Interaction Score: 1.32

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22896685

Sources:
CIViC
DOXORUBICIN SLC22A16

Interaction Score: 0.88

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28036387 20179710 17559346

Sources:
PharmGKB
DOXORUBICIN SDHB

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6672210 16278810

Sources:
NCI
DOXORUBICIN SETD4

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19204081

Sources:
PharmGKB
DOXORUBICIN AKR7A2

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20837989

Sources:
PharmGKB
DOXORUBICIN RAC2

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526

Sources:
PharmGKB
DOXORUBICIN CBR1

Interaction Score: 0.66

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526 19204081 19022938 19016765

Sources:
PharmGKB
DOXORUBICIN CBR3

Interaction Score: 0.53

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526 20007405 18551042

Sources:
PharmGKB
DOXORUBICIN RPSA

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11493465

Sources:
NCI
DOXORUBICIN MYB

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15001837

Sources:
NCI
DOXORUBICIN ZEB1

Interaction Score: 0.44

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24013721

Sources:
CIViC
DOXORUBICIN H2AX

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15489221

Sources:
NCI
DOXORUBICIN GSTA1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 24215845 19448608

Sources:
PharmGKB
DOXORUBICIN AKR1C3

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23116553 21048526 20837989

Sources:
PharmGKB
DOXORUBICIN GADD45A

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7729953

Sources:
NCI
DOXORUBICIN IL11

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9363868

Sources:
NCI
DOXORUBICIN EZH2

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ACY-957 + Doxorubicin

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type sensitive

PMIDs:
25605023

Sources:
JAX-CKB
DOXORUBICIN NOS3

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 25545243 21048526 19671875

Sources:
PharmGKB
DOXORUBICIN ATRX

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26936505

Sources:
JAX-CKB
DOXORUBICIN MYOD1

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8119948

Sources:
NCI
DOXORUBICIN BMP7

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
DOXORUBICIN NQO2

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 21946896

Sources:
PharmGKB
DOXORUBICIN LINC00251

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
DOXORUBICIN DOK5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26590194

Sources:
PharmGKB
DOXORUBICIN TOP2A

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name AEZS-108, AN-152

Novel drug target Established target

Trial Name MTC-DOX, MTC-doxorubicin

PMIDs:
21388138 26211460 22276998 20170164 17016621 17351394 17010609 17578914 11752352 17089011

Sources:
DTC TdgClinicalTrial ClearityFoundationClinicalTrial TEND
DOXORUBICIN ALDH3A1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN SLC28A3

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN EDN1

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11589785

Sources:
NCI
DOXORUBICIN CDKN1B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12576455

Sources:
NCI
DOXORUBICIN AFP

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15770640

Sources:
NCI
DOXORUBICIN GATA3

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24141364

Sources:
PharmGKB
DOXORUBICIN NQO1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10954045 9333325

Sources:
PharmGKB
DOXORUBICIN NT5E

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7927909

Sources:
NCI
DOXORUBICIN ABCC3

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22016816

Sources:
DTC PharmGKB
DOXORUBICIN FCGR3B

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1830717

Sources:
NCI
DOXORUBICIN XRCC1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN CYP1A1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15588138

Sources:
NCI
DOXORUBICIN NOS2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526

Sources:
PharmGKB
DOXORUBICIN TOP2B

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526

Sources:
ClearityFoundationClinicalTrial PharmGKB TTD
DOXORUBICIN TGM2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18174247

Sources:
NCI
DOXORUBICIN GSTM1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23323945

Sources:
PharmGKB
DOXORUBICIN ALK

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Dalantercept + Doxorubicin

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
16880530 28455243 26373572

Sources:
JAX-CKB NCI
DOXORUBICIN FCGR3A

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1830717

Sources:
NCI
DOXORUBICIN UGT1A6

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN ABCC4

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19696793

Sources:
PharmGKB
DOXORUBICIN CYP2B6

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344 20179710

Sources:
PharmGKB
DOXORUBICIN RARG

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN ERCC1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN RUNX1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy I-CBP112 + Doxorubicin

Indication/Tumor Type leukemia

Response Type sensitive

PMIDs:
26552700

Sources:
JAX-CKB
DOXORUBICIN ATM

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23585524

Sources:
CIViC PharmGKB
DOXORUBICIN BIRC5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16211302

Sources:
NCI
DOXORUBICIN TGFB1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12956904

Sources:
NCI
DOXORUBICIN NOS1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21048526

Sources:
PharmGKB
DOXORUBICIN NTRK2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12438277

Sources:
NCI
DOXORUBICIN BCL2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16749867

Sources:
NCI
DOXORUBICIN TOP1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21094049 17276690 19053767

Sources:
DTC
DOXORUBICIN MAPK14

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16905201 15557793

Sources:
NCI
DOXORUBICIN GSTP1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11351295

Sources:
PharmGKB
DOXORUBICIN BAX

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12040435

Sources:
NCI
DOXORUBICIN ABCC1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16330681

Sources:
PharmGKB
DOXORUBICIN KMT2A

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy I-CBP112 + Doxorubicin

Indication/Tumor Type leukemia

Response Type predicted – sensitive

PMIDs:
26552700

Sources:
JAX-CKB
DOXORUBICIN SLCO1B1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB
DOXORUBICIN PIK3CB

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16905201

Sources:
NCI
DOXORUBICIN ABCC2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16330681

Sources:
PharmGKB
DOXORUBICIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11408511 29938344 22016816 25637052 18377430 25582575 18408561

Sources:
NCI PharmGKB
DOXORUBICIN SRC

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7532928

Sources:
NCI
DOXORUBICIN CYP1B1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN PIK3CA

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Bevacizumab + Doxorubicin + Temsirolimus

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
27893038 16905201 12761490

Sources:
JAX-CKB NCI
DOXORUBICIN TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Avastin + Doxorubicin + Docetaxel

Indication/Tumor Type breast cancer

Response Type sensitive

PMIDs:
26826118 23165797 16243804 25658463 21399868 17363498 9569050 22698404 26288684 24065105

Sources:
DTC JAX-CKB CIViC
DOXORUBICIN ABCG2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11956086

Sources:
PharmGKB
DOXORUBICIN BDNF

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10728907

Sources:
NCI
DOXORUBICIN CYP19A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
DOXORUBICIN G6PD

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
539595

Sources:
PharmGKB
DOXORUBICIN AKT1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lymphoma

Response Type decreased response

Approval Status Preclinical - Cell line xenograft

PMIDs:
18708578

Sources:
JAX-CKB
DOXORUBICIN PIK3CG

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16905201

Sources:
NCI
DOXORUBICIN BRAF

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy PLX4720 + Doxorubicin

Indication/Tumor Type melanoma

Response Type sensitive

PMIDs:
27924459

Sources:
JAX-CKB
DOXORUBICIN BRCA1

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12698198

Sources:
NCI
DOXORUBICIN NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27561454

Sources:
PharmGKB
DOXORUBICIN CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300 29938344 20179710

Sources:
DTC PharmGKB
DOXORUBICIN ERBB2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Guideline

Response Type sensitive

PMIDs:
None found

Sources:
JAX-CKB
DOXORUBICIN APEX1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOXORUBICIN ALDH1A1

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29938344

Sources:
PharmGKB
DOXORUBICIN CYP2C9

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
DOXORUBICIN CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15465924 9187528

Sources:
NCI PharmGKB
DOXORUBICIN POLK

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
DOXORUBICIN CYP1A2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
DOXORUBICIN CYP2D6

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
DOXORUBICIN NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18413364

Sources:
NCI

TEND: DOXORUBICIN
- Version: 01-August-2011
Alternate Names:

DOXORUBICIN Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1974

Publications:
TdgClinicalTrial: DOXORUBICIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class Small Molecule

FDA Approval approved

Publications:

DTC: DOXORUBICIN

Version: 02-September-2020

Alternate Names:

CHEMBL53463 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Kozakai Y et al., 2014, Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line., Bioorg Med Chem Lett

Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem

NCI: DOXORUBICIN

Version: 14-September-2017

Alternate Names:

C456 NCI drug code

Drug Info:

Publications:

Vikhanskaya et al., 1995, Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes., Int. J. Cancer

Bosanquet et al., 2002, Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia., Leukemia

Tassone et al., 2003, BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells., Br. J. Cancer

JAX-CKB: Doxorubicin

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Richter et al., 2015, WIP1 phosphatase as a potential therapeutic target in neuroblastoma., PLoS ONE

Yang et al., 2011, p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer., Int. J. Oncol.

Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.

PharmGKB: doxorubicin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Wojnowski L et al., 2005, NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity., Circulation

Altés A et al., 2013, Pharmacogenetic analysis in the treatment of Hodgkin lymphoma., Leuk Lymphoma

Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood

CIViC: DOXORUBICIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Jackson et al., 2012, p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer., Cancer Cell

Wong RP et al., 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3., Mol Cancer Ther

Berns et al., 1998, Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer., Br. J. Cancer

TTD: Doxorubicin
- Version: 2020.06.01
Alternate Names:

D07VLY TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL53463
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ClearityFoundationClinicalTrial: DOXORUBICIN
- Version: 15-June-2013
Alternate Names:

Drug Info:

Publications:

combination therapy	ACY-957 + Doxorubicin
Indication/Tumor Type	diffuse large B-cell lymphoma
Response Type	sensitive

Approval Status	Preclinical
Indication/Tumor Type	glioblastoma multiforme
Response Type	sensitive

Trial Name	AEZS-108, AN-152
Novel drug target	Established target
Trial Name	MTC-DOX, MTC-doxorubicin

combination therapy	Dalantercept + Doxorubicin
Indication/Tumor Type	melanoma
Response Type	sensitive

combination therapy	I-CBP112 + Doxorubicin
Indication/Tumor Type	leukemia
Response Type	sensitive

combination therapy	Bevacizumab + Doxorubicin + Temsirolimus
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	predicted – sensitive

combination therapy	Avastin + Doxorubicin + Docetaxel
Indication/Tumor Type	breast cancer
Response Type	sensitive

Indication/Tumor Type	lymphoma
Response Type	decreased response
Approval Status	Preclinical - Cell line xenograft

combination therapy	PLX4720 + Doxorubicin
Indication/Tumor Type	melanoma
Response Type	sensitive

Evidence Type	Actionable
Approval Status	Guideline
Response Type	sensitive

DOXORUBICIN Drug Record

DOXORUBICIN chembl:CHEMBL53463 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28763429 28485375 26799497 21048526 19448608 16330681

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28485375 25823784 21048526 19448608 16330681

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25466181

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21048526

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17511886

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10070062

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22896685

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28036387 20179710 17559346

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6672210 16278810

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 19204081

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20837989

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21048526

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21048526 19204081 19022938 19016765

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21048526 20007405 18551042

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11493465

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15001837

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24013721

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15489221

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29938344 24215845 19448608

Interaction Types & Directionality:

n/a

PMIDs:
28763429 28485375 26799497 21048526 19448608 16330681

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
28485375 25823784 21048526 19448608 16330681

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25466181

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
21048526

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
17511886

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10070062

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
22896685

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
28036387 20179710 17559346

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
6672210 16278810

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
19204081

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20837989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21048526

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21048526 19204081 19022938 19016765

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21048526 20007405 18551042

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11493465

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15001837

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
24013721

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
15489221

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
29938344 24215845 19448608

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
23116553 21048526 20837989

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
7729953

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9363868

Sources:
NCI

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy ACY-957 + Doxorubicin

Indication/Tumor Type diffuse large B-cell lymphoma

Response Type sensitive

PMIDs:
25605023

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
29938344 25545243 21048526 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical

Indication/Tumor Type glioblastoma multiforme

Response Type sensitive

PMIDs:
26936505

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
8119948

Sources:
NCI